The Impact of Medication Adherence in Patients With Type 2 Diabetes and Disabilities
Impact of Medication Adherence on Cardiovascular Outcomes in Individuals With Type 2 Diabetes and Disabilities: Nationwide Cohort Study
1 other identifier
observational
365,295
0 countries
N/A
Brief Summary
Individuals with disabilities and type 2 diabetes tend to have worse clinical outcomes. To identify modifiable factors that may improve these outcomes, the investigators evaluated the role of medication adherence. A retrospective, cohort study was conducted using data from the Korean National Health Insurance Service (K-NHIS) database.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2010
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2023
CompletedFirst Submitted
Initial submission to the registry
June 28, 2025
CompletedFirst Posted
Study publicly available on registry
July 6, 2025
CompletedJuly 10, 2025
July 1, 2025
13.2 years
June 28, 2025
July 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Major adverse cardiac and cerebrovascular events (MACCE)
Composite of MI, ischemic stroke, hemorrhagic stroke, and all-cause mortality
10 years after diagnosed T2DM
Secondary Outcomes (5)
Diabetic neuropathy
10 years after diagnosed T2DM
Diabetic foot without amputation
10 years after diagnosed T2DM
Diabetic foot with amputation
10 years after diagnosed T2DM
Proliferative diabetic retinopathy
10 years after diagnosed T2DM
Non-proliferative diabetic retinopathy
10 years after diagnosed T2DM
Study Arms (2)
Disability
Individuals were classified as having a disability if they were officially registered as of the index date. Physical disability included conditions such as limb impairment, brain lesion, visual or auditory impairment, speech impairment, facial disfigurement, and epilepsy. Mental disability included intellectual disability, autism spectrum disorder, and psychiatric disorders.
No disability
Individuals who were not officially registered with any physical or mental disability as of the index date.
Interventions
Patients with poor adherence was defined as medication possession ratio(MPR) \<50%.
Patients with good adherence was defined as medication possession ratio(MPR) ≥50%.
Eligibility Criteria
Patients newly diagnosed with T2DM and without prior major cardiovascular or malignant conditions.
You may qualify if:
- Patients who newly diagnosed T2DM between between January 1, 2010, and December 31, 2023
You may not qualify if:
- individuals with a history of MI, stroke, percutaneous coronary intervention, peripheral arterial disease, chronic kidney disease, or cancer before the diagnosis of diabetes were excluded.
- individuals with who already had diabetics related complication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 28, 2025
First Posted
July 6, 2025
Study Start
January 1, 2010
Primary Completion
March 30, 2023
Study Completion
September 30, 2023
Last Updated
July 10, 2025
Record last verified: 2025-07